Clinical Trial Update: 68Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis.

View source ↗

Summary

A recruiting clinical trial evaluating 68Ga-FAPI PET/CT imaging for diagnosing, grading, and evaluating efficacy in primary myelofibrosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• 68Ga-FAPI (gallium-68 labeled fibroblast activation protein inhibitor)

Snippet

Sponsor: The First Affiliated Hospital of Xiamen University | Conditions: Primary Myelofibrosis | Status: RECRUITING